Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Vascular Malformations 1Unresectable Locally Advanced or Metastatic Solid Tumors 1Triple Negative Breast Neoplasms 1Skin Neoplasms 1Phase IB 1Nevus 1Neoplasms, Plasma Cell 1Lymphoma 1Lymphangioma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hemangioma 1Hemangioendothelioma 1Hamartoma Syndrome, Multiple 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Bone Neoplasms 1Autistic Disorder 1Arteriovenous Malformations 1

Interventions

regorafenib 1Paclitaxel 1Everolimus 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Unresectable Locally Advanced or Metastatic Solid Tumors × Everolimus × Clear all
NCT06682611 2024-11-12

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

Shanghai Runshi Pharmaceutical Technology Co., Ltd

Phase 1/2 Not yet recruiting
380 enrolled
Other solid neoplasm

Unresectable Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡